Unknown

Dataset Information

0

A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.


ABSTRACT: Antibody treatment is currently the only available countermeasure for botulism, a fatal illness caused by flaccid paralysis of muscles due to botulinum neurotoxin (BoNT) intoxication. Among the seven major serotypes of BoNT/A-G, BoNT/A poses the most serious threat to humans because of its high potency and long duration of action. Prior to entering neurons and blocking neurotransmitter release, BoNT/A recognizes motoneurons via a dual-receptor binding process in which it engages both the neuron surface polysialoganglioside (PSG) and synaptic vesicle glycoprotein 2 (SV2). Previously, we identified a potent neutralizing antitoxin against BoNT/A1 termed ciA-C2, derived from a camelid heavy-chain-only antibody (VHH). In this study, we demonstrate that ciA-C2 prevents BoNT/A1 intoxication by inhibiting its binding to neuronal receptor SV2. Furthermore, we determined the crystal structure of ciA-C2 in complex with the receptor-binding domain of BoNT/A1 (HCA1) at 1.68?Å resolution. The structure revealed that ciA-C2 partially occupies the SV2-binding site on HCA1, causing direct interference of HCA1 interaction with both the N-glycan and peptide-moiety of SV2. Interestingly, this neutralization mechanism is similar to that of a monoclonal antibody in clinical trials, despite that ciA-C2 is more than 10-times smaller. Taken together, these results enlighten our understanding of BoNT/A1 interactions with its neuronal receptor, and further demonstrate that inhibiting toxin binding to the host receptor is an efficient countermeasure strategy.

SUBMITTER: Yao G 

PROVIDER: S-EPMC5547058 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.

Yao Guorui G   Lam Kwok-Ho KH   Weisemann Jasmin J   Peng Lisheng L   Krez Nadja N   Perry Kay K   Shoemaker Charles B CB   Dong Min M   Rummel Andreas A   Jin Rongsheng R  

Scientific reports 20170807 1


Antibody treatment is currently the only available countermeasure for botulism, a fatal illness caused by flaccid paralysis of muscles due to botulinum neurotoxin (BoNT) intoxication. Among the seven major serotypes of BoNT/A-G, BoNT/A poses the most serious threat to humans because of its high potency and long duration of action. Prior to entering neurons and blocking neurotransmitter release, BoNT/A recognizes motoneurons via a dual-receptor binding process in which it engages both the neuron  ...[more]

Similar Datasets

| S-EPMC10681988 | biostudies-literature
| S-EPMC8207222 | biostudies-literature
| S-EPMC2946066 | biostudies-literature
| S-EPMC5583347 | biostudies-literature
| S-EPMC5869393 | biostudies-literature
| S-EPMC5360321 | biostudies-literature
| S-EPMC8472335 | biostudies-literature
| S-EPMC6774440 | biostudies-literature
| S-EPMC2903050 | biostudies-literature
| S-EPMC9971915 | biostudies-literature